Pfizer strikes another immunotherapy deal to widen its oncology pipeline

  • Pfizer,oncology pipeline,AstraZeneca

With its designs on AstraZeneca ($AZN) at least temporarily abandoned, Pfizer ($PFE) has set out to create an immuno-oncology portfolio of its own, signing a deal with a Belgian biotech to get its hands on treatments that promise to sharpen the body's anticancer weaponry.

Pfizer has agreed to pay iTeos Therapeutics €24 million ($30 million) up front for the exclusive rights to some preclinical candidates, also making an undisclosed equity investment in the company and promising untold milestone payments down the line.

Through the deal, Pfizer gets some early-stage drugs that target IDO1 and TDO2, cancer-expressed enzymes that break down tryptophan, which is integral to the immune system's ability to recognize tumors. By blocking the enzymes, iTeos' candidates can unblind the body's defenses and help T cells better attack malignancies, Pfizer said. And, beyond collaborating on IDO1 and TDO2 blockers, iTeo and Pfizer have agreed to work together to discover and validate new immuno-oncology targets.

The deal could be read as further evidence that Pfizer has moved on from its pursuit of AstraZeneca, a $118 billion gambit driven largely by the allure of the latter company's oncology pipeline. Last month, Pfizer signed up to pay Merck KGaA $850 million up front and as much as $2 billion more in order to cut in on a host of cancer immunotherapies, a sign the company is committed to catching up with the leaders in the space, a group that includes Merck ($MRK), Bristol-Myers Squibb ($BMY) and Roche ($RHHBY).

"This collaboration with iTeos is another important step for Pfizer as we continue to build an industry-leading pipeline of cancer immunotherapeutics, a critical facet of which is the promising class of small-molecule immunomodulators," Pfizer Oncology Chief Scientific Officer Robert Abraham said in a statement. "With iTeos' strong expertise and experience in tumor immunology, this collaboration is well-positioned to help us deliver on our commitment to help bring new therapies to patients."

As for iTeos, Pfizer's co-sign is big news for a small biotech in the early days of operation. The Gosselies, Belgium-headquartered company was formed in 2012 by Ludwig Cancer Research and Universite Catholique de Louvain, raising €9 million ($11 million) in seed funding to build out an oncology discovery platform.

This link:

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus


Related News

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

2015/10/20 - Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.

AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology clinical study

2014/07/31 - AstraZeneca announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase I/Ib immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumours.

Pfizer Completes Acquisition Of InnoPharma

2014/09/26 - Pfizer Inc. (PFE) today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions.

FDA reviewers say Pfizer's Chantix should keep its black box

2014/10/20 - FDA staffers aren't as impressed with new safety data on Chantix as Pfizer ($PFE) wants them to be. In briefing documents filed in advance of Thursday's advisory committee meeting, reviewers say the stop-smoking remedy should keep its black-box warning about potential psychiatric side effects.

FDA panel votes to keep severe warning on Pfizer anti-smoking drug

2014/10/20 - Pfizer Inc failed to convince the U.S. Food and Drug Administration to remove a black box warning on its controversial quit-smoking drug Chantix, with an advisory panel to the agency voting against the removal on Thursday.

AstraZeneca advances tralokinumab to Phase III in severe asthma

2014/08/15 - AstraZeneca today announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm.